These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 29800648

  • 1. Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity.
    Edwards ESJ, Bier J, Cole TS, Wong M, Hsu P, Berglund LJ, Boztug K, Lau A, Gostick E, Price DA, O'Sullivan M, Meyts I, Choo S, Gray P, Holland SM, Deenick EK, Uzel G, Tangye SG.
    J Allergy Clin Immunol; 2019 Jan; 143(1):276-291.e6. PubMed ID: 29800648
    [Abstract] [Full Text] [Related]

  • 2. Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8+ T Cell Survival, Differentiation, and Function.
    Cannons JL, Preite S, Kapnick SM, Uzel G, Schwartzberg PL.
    Front Immunol; 2018 Jan; 9():1758. PubMed ID: 30116245
    [Abstract] [Full Text] [Related]

  • 3. Herpesviruses in the Activated Phosphatidylinositol-3-Kinase-δ Syndrome.
    Cohen JI.
    Front Immunol; 2018 Jan; 9():237. PubMed ID: 29599765
    [Abstract] [Full Text] [Related]

  • 4. Exhaustion of the CD8+ T Cell Compartment in Patients with Mutations in Phosphoinositide 3-Kinase Delta.
    Wentink MWJ, Mueller YM, Dalm VASH, Driessen GJ, van Hagen PM, van Montfrans JM, van der Burg M, Katsikis PD.
    Front Immunol; 2018 Jan; 9():446. PubMed ID: 29563914
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome.
    Luo Y, Xia Y, Wang W, Li Z, Jin Y, Gong Y, He T, Li Q, Li C, Yang J.
    Clin Immunol; 2018 Dec; 197():60-67. PubMed ID: 30138677
    [Abstract] [Full Text] [Related]

  • 7. Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4+ T cells.
    Bier J, Rao G, Payne K, Brigden H, French E, Pelham SJ, Lau A, Lenthall H, Edwards ESJ, Smart JM, Cole TS, Choo S, Joshi AY, Abraham RS, O'Sullivan M, Boztug K, Meyts I, Gray PE, Berglund LJ, Hsu P, Wong M, Holland SM, Notarangelo LD, Uzel G, Ma CS, Brink R, Tangye SG, Deenick EK.
    J Allergy Clin Immunol; 2019 Jul; 144(1):236-253. PubMed ID: 30738173
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
    Albanese M, Tagawa T, Bouvet M, Maliqi L, Lutter D, Hoser J, Hastreiter M, Hayes M, Sugden B, Martin L, Moosmann A, Hammerschmidt W.
    Proc Natl Acad Sci U S A; 2016 Oct 18; 113(42):E6467-E6475. PubMed ID: 27698133
    [Abstract] [Full Text] [Related]

  • 11. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases.
    Latour S, Fischer A.
    Immunol Rev; 2019 Sep 18; 291(1):174-189. PubMed ID: 31402499
    [Abstract] [Full Text] [Related]

  • 12. Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells.
    Rodriguez R, Fournier B, Cordeiro DJ, Winter S, Izawa K, Martin E, Boutboul D, Lenoir C, Fraitag S, Kracker S, Watts TH, Picard C, Bruneau J, Callebaut I, Fischer A, Neven B, Latour S.
    J Exp Med; 2019 Dec 02; 216(12):2800-2818. PubMed ID: 31537641
    [Abstract] [Full Text] [Related]

  • 13. When to suspect inborn errors of immunity in Epstein-Barr virus-related lymphoproliferative disorders.
    Sacco KA, Notarangelo LD, Delmonte OM.
    Clin Microbiol Infect; 2023 Apr 02; 29(4):457-462. PubMed ID: 36209991
    [Abstract] [Full Text] [Related]

  • 14. [Clinical and immunological analysis of patients with activated phosphoinositide 3-kinase δ syndrome resulting from PIK3CD mutation].
    Tang WJ, Wang W, Luo Y, Wang YP, Li L, An YF, Gou LJ, Ma MS, He TY, Yang J, Zhao XD, Song HM.
    Zhonghua Er Ke Za Zhi; 2017 Jan 02; 55(1):19-24. PubMed ID: 28072954
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism.
    Serafini B, Rosicarelli B, Veroni C, Mazzola GA, Aloisi F.
    J Virol; 2019 Dec 15; 93(24):. PubMed ID: 31578295
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.
    Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, Avery DT, Moens L, Cannons JL, Biancalana M, Stoddard J, Ouyang W, Frucht DM, Rao VK, Atkinson TP, Agharahimi A, Hussey AA, Folio LR, Olivier KN, Fleisher TA, Pittaluga S, Holland SM, Cohen JI, Oliveira JB, Tangye SG, Schwartzberg PL, Lenardo MJ, Uzel G.
    Nat Immunol; 2014 Jan 15; 15(1):88-97. PubMed ID: 24165795
    [Abstract] [Full Text] [Related]

  • 19. Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and γδ T cells.
    Djaoud Z, Guethlein LA, Horowitz A, Azzi T, Nemat-Gorgani N, Olive D, Nadal D, Norman PJ, Münz C, Parham P.
    J Exp Med; 2017 Jun 05; 214(6):1827-1841. PubMed ID: 28468758
    [Abstract] [Full Text] [Related]

  • 20. The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis.
    Veroni C, Aloisi F.
    Front Immunol; 2021 Jun 05; 12():665718. PubMed ID: 34305896
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.